Haley Price: Ledger

Stories naming Haley Price. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Role	Organisation	Sources
	Buchan Consulting	GBS Ventures (12 Dec 2013), GBS Ventures (31 Oct 2013)

Unnamed stage $12.6m

HATCHTECH COMPLETES $12.6M CAPITAL RAISE

Melbourne drug developer Hatchtech raised A$12.6 million, with OneVentures Innovation Fund leading, to advance its head lice treatment toward Phase III trials; board changes brought in Richard Treagus and Hugh Alsop.

GBS Ventures 31 Oct 2013 Hatchtech Acrux AustralianSuper Buchan Consulting GBS Ventures Neuren Pharmaceuticals University of Melbourne Endowment Australian Government Blue Sky Alternative Investments OneVentures Innovation Fund Queensland Biotechnology Fund Uniseed University of Melbourne Haley Price Hugh Alsop Dr John Kurek Dr Ross Macdonald

Haley Price

Roles

Coverage

HATCHTECH RECEIVES FDA SPECIAL PROTOCOL AGREEMENT OF DEOVO PHASE III STUDIES

HATCHTECH COMPLETES $12.6M CAPITAL RAISE